CD8⁺ T cells in multiple sclerosis

Bibliography

• Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343:938-52
   PubMed Web of Science ®Google Scholar
• Kappos L, Comi G, Panitch H, et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 2000;6:1176-82
   PubMed Web of Science ®Google Scholar
• Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000;6:1167-75
   PubMed Web of Science ®Google Scholar
• Rivera-Quinones C, McGavern D, Schmelzer JD, et al. Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. Nat Med 1998;4:187-93
   PubMed Web of Science ®Google Scholar
• Howe CL, Adelson JD, Rodriguez M. Absence of perforin expression confers axonal protection despite demyelination. Neurobiol Dis 2007;25:354-9
   PubMedGoogle Scholar
• Denic A, Pirko I, Wootla B, et al. Deletion of beta-2-microglobulin ameliorates spinal cord lesion load and promotes recovery of brainstem NAA levels in a murine model of multiple sclerosis. Brain Pathol 2012;22:698-708
   PubMedGoogle Scholar
• Rodriguez M, Sriram S. Successful therapy of Theiler's virus-induced demyelination (DA strain) with monoclonal anti-Lyt-2 antibody. J Immunol 1988;140:2950-5
   PubMed Web of Science ®Google Scholar
• Huseby ES, Liggitt D, Brabb T, et al. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med 2001;194:669-76
   PubMed Web of Science ®Google Scholar
• Sun D, Whitaker JN, Huang Z, et al. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol 2001;166:7579-87
   PubMed Web of Science ®Google Scholar
• Markovic-Plese S, McFarland HF. Immunopathogenesis of the multiple sclerosis lesion. Curr Neurol Neurosci Rep 2001;1:257-62
   PubMedGoogle Scholar
• Weiner HL. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol 2004;61:1613-15
   PubMed Web of Science ®Google Scholar
• Friese MA, Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain 2005;128:1747-63
   PubMed Web of Science ®Google Scholar
• Goverman J, Perchellet A, Huseby ES. The role of CD8(+) T cells in multiple sclerosis and its animal models. Curr Drug Targets Inflamm Allergy 2005;4:239-45
   PubMedGoogle Scholar
• Lassmann H, Ransohoff RM. The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal. Trends Immunol 2004;25:132-7
   PubMed Web of Science ®Google Scholar
• Babbe H, Roers A, Waisman A, et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000;192:393-404
   PubMed Web of Science ®Google Scholar
• Skulina C, Schmidt S, Dornmair K, et al. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci USA 2004;101:2428-33
   PubMed Web of Science ®Google Scholar
• Hoftberger R, Aboul-Enein F, Brueck W, et al. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol 2004;14:43-50
   PubMed Web of Science ®Google Scholar
• van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 1997;49:351-7
   PubMed Web of Science ®Google Scholar
• Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-801
   PubMed Web of Science ®Google Scholar
• Liblau RS, Wong FS, Mars LT, et al. Autoreactive CD8 T cells in organ-specific autoimmunity: emerging targets for therapeutic intervention. Immunity 2002;17:1-6
   PubMed Web of Science ®Google Scholar
• Johnson AJ, Suidan GL, McDole J, et al. The CD8 T cell in multiple sclerosis: suppressor cell or mediator of neuropathology? Int Rev Neurobiol 2007;79:73-97
   PubMed Web of Science ®Google Scholar
• Booss J, Esiri MM, Tourtellotte WW, et al. Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J Neurol Sci 1983;62:219-32
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bhan AK, Gilles F, et al. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol 1986;19:578-87
   PubMed Web of Science ®Google Scholar
• Monteiro J, Hingorani R, Pergolizzi R, et al. Clonal dominance of CD8+ T-cell in multiple sclerosis. Ann NY Acad Sci 1995;756:310-12
   PubMed Web of Science ®Google Scholar
• Jacobsen M, Cepok S, Quak E, et al. Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 2002;125:538-50
   PubMed Web of Science ®Google Scholar
• Junker A, Ivanidze J, Malotka J, et al. Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain 2007;130:2789-99
   PubMedGoogle Scholar
• Jilek S, Schluep M, Rossetti AO, et al. CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis. Clin Immunol 2007;123:105-13
   PubMed Web of Science ®Google Scholar
• Malmestrom C, Lycke J, Haghighi S, et al. Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSF. J Neuroimmunol 2008;196:159-65
   PubMed Web of Science ®Google Scholar
• Jilek S, Schluep M, Meylan P, et al. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 2008;131:1712-21
   PubMedGoogle Scholar
• Fotheringham J, Jacobson S. Human herpesvirus 6 and multiple sclerosis: potential mechanisms for virus-induced disease. Herpes 2005;12:4-9
   PubMedGoogle Scholar
• Cheng W, Ma Y, Gong F, et al. Cross-reactivity of autoreactive T cells with MBP and viral antigens in patients with MS. Front Biosci 2012;17:1648-58
   Google Scholar
• Neumann H, Medana IM, Bauer J, et al. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002;25:313-19
   PubMed Web of Science ®Google Scholar
• Huseby ES, Huseby PG, Shah S, et al. Pathogenic CD8 T cells in multiple sclerosis and its experimental models. Front Immunol 2012;3:64
   PubMed Web of Science ®Google Scholar
• Neumann H, Cavalie A, Jenne DE, et al. Induction of MHC class I genes in neurons. Science 1995;269:549-52
   PubMed Web of Science ®Google Scholar
• Medana I, Li Z, Flugel A, et al. Fas ligand (CD95L) protects neurons against perforin-mediated T lymphocyte cytotoxicity. J Immunol 2001;167:674-81
   PubMedGoogle Scholar
• Jurewicz A, Biddison WE, Antel JP. MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes. J Immunol 1998;160:3056-9
   PubMed Web of Science ®Google Scholar
• Pouly S, Becher B, Blain M, et al. Interferon-gamma modulates human oligodendrocyte susceptibility to Fas-mediated apoptosis. J Neuropathol Exp Neurol 2000;59:280-6
   PubMedGoogle Scholar
• Rensing-Ehl A, Malipiero U, Irmler M, et al. Neurons induced to express major histocompatibility complex class I antigen are killed via the perforin and not the Fas (APO-1/CD95) pathway. Eur J Immunol 1996;26:2271-4
   PubMedGoogle Scholar
• Medana IM, Gallimore A, Oxenius A, et al. MHC class I-restricted killing of neurons by virus-specific CD8+ T lymphocytes is effected through the Fas/FasL, but not the perforin pathway. Eur J Immunol 2000;30:3623-33
   PubMed Web of Science ®Google Scholar
• Khanna KM, Bonneau RH, Kinchington PR, et al. Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 2003;18:593-603
   PubMed Web of Science ®Google Scholar
• Medana I, Martinic MA, Wekerle H, et al. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am J Pathol 2001;159:809-15
   PubMed Web of Science ®Google Scholar
• Bien CG, Bauer J, Deckwerth TL, et al. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis. Ann Neurol 2002;51:311-18
   PubMed Web of Science ®Google Scholar
• Bitsch A, Schuchardt J, Bunkowski S, et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000;123(Pt 6):1174-83
   PubMedGoogle Scholar
• Kuhlmann T, Lingfeld G, Bitsch A, et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002;125:2202-12
   PubMed Web of Science ®Google Scholar
• Denic A, Macura SI, Warrington AE, et al. A single dose of neuron-binding human monoclonal antibody improves spontaneous activity in a murine model of demyelination. PLoS ONE 2011;6:e26001
   PubMedGoogle Scholar
• Lucchinetti CF, Bruck W, Lassmann H. Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol 2004;56:308
   PubMed Web of Science ®Google Scholar
• Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-17
   PubMed Web of Science ®Google Scholar
• Naito S, Namerow N, Mickey MR, et al. Multiple sclerosis: association with HL-A3. Tissue Antigens 1972;2:1-4
   PubMedGoogle Scholar
• Jersild C, Svejgaard A, Fog T. HL-A antigens and multiple sclerosis. Lancet 1972;1:1240-1
   PubMed Web of Science ®Google Scholar
• Fogdell-Hahn A, Ligers A, Gronning M, et al. Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 2000;55:140-8
   PubMedGoogle Scholar
• Harbo HF, Lie BA, Sawcer S, et al. Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens 2004;63:237-47
   PubMedGoogle Scholar
• Brynedal B, Duvefelt K, Jonasdottir G, et al. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS One 2007;2:e664
   PubMedGoogle Scholar
• Denic A, Johnson AJ, Bieber AJ, et al. The relevance of animal models in multiple sclerosis research. Pathophysiology 2011;18:21-9
   PubMedGoogle Scholar
• Jiang H, Zhang SI, Pernis B. Role of CD8+ T cells in murine experimental allergic encephalomyelitis. Science 1992;256:1213-15
   PubMed Web of Science ®Google Scholar
• Koh DR, Fung-Leung WP, Ho A, et al. Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/- mice. Science 1992;256:1210-13
   PubMed Web of Science ®Google Scholar
• Ford ML, Evavold BD. Specificity, magnitude, and kinetics of MOG-specific CD8+ T cell responses during experimental autoimmune encephalomyelitis. Eur J Immunol 2005;35:76-85
   PubMed Web of Science ®Google Scholar
• Saxena A, Bauer J, Scheikl T, et al. Cutting edge: multiple sclerosis-like lesions induced by effector CD8 T cells recognizing a sequestered antigen on oligodendrocytes. J Immunol 2008;181:1617-21
   PubMed Web of Science ®Google Scholar
• Sobottka B, Harrer MD, Ziegler U, et al. Collateral bystander damage by myelin-directed CD8+ T cells causes axonal loss. Am J Pathol 2009;175:1160-6
   PubMedGoogle Scholar
• Ji Q, Castelli L, Goverman JM. MHC class I-restricted myelin epitopes are cross-presented by Tip-DCs that promote determinant spreading to CD8(+) T cells. Nat Immunol 2013;14:254-61
   PubMedGoogle Scholar
• Rodriguez M, Rivera-Quinones C, Murray PD, et al. The role of CD4+ and CD8+ T cells in demyelinating disease following Theiler's virus infection: a model for multiple sclerosis. J Neurovirol 1997;3(Suppl 1):S43-5
   PubMedGoogle Scholar
• Moll C, Mourre C, Lazdunski M, et al. Increase of sodium channels in demyelinated lesions of multiple sclerosis. Brain Res 1991;556:311-16
   PubMed Web of Science ®Google Scholar
• Murray PD, McGavern DB, Lin X, et al. Perforin-dependent neurologic injury in a viral model of multiple sclerosis. J Neurosci 1998;18:7306-14
   PubMed Web of Science ®Google Scholar
• Deb C, Lafrance-Corey RG, Zoecklein L, et al. Demyelinated axons and motor function are protected by genetic deletion of perforin in a mouse model of multiple sclerosis. J Neuropathol Exp Neurol 2009;68:1037-48
   PubMed Web of Science ®Google Scholar
• Ure DR, Rodriguez M. Preservation of neurologic function during inflammatory demyelination correlates with axon sparing in a mouse model of multiple sclerosis. Neuroscience 2002;111:399-411
   PubMed Web of Science ®Google Scholar
• Johnson AJ, Upshaw J, Pavelko KD, et al. Preservation of motor function by inhibition of CD8+ virus peptide-specific T cells in Theiler's virus infection. Faseb J 2001;15:2760-2
   PubMed Web of Science ®Google Scholar
• Johnson AJ, Njenga MK, Hansen MJ, et al. Prevalent class I-restricted T-cell response to the Theiler's virus epitope Db:VP2121-130 in the absence of endogenous CD4 help, tumor necrosis factor alpha, gamma interferon, perforin, or costimulation through CD28. J Virol 1999;73:3702-8
   PubMedGoogle Scholar
• Howe CL, Ure D, Adelson JD, et al. CD8+ T cells directed against a viral peptide contribute to loss of motor function by disrupting axonal transport in a viral model of fulminant demyelination. J Neuroimmunol 2007;188:13-21
   PubMedGoogle Scholar
• Rodriguez M, Lindsley MD. Immunosuppression promotes CNS remyelination in chronic virus-induced demyelinating disease. Neurology 1992;42:348-57
   PubMedGoogle Scholar
• Miller DJ, Rivera-Quinones C, Njenga MK, et al. Spontaneous CNS remyelination in beta 2 microglobulin-deficient mice following virus-induced demyelination. J Neurosci 1995;15:8345-52
   PubMedGoogle Scholar
• Murray PD, Pavelko KD, Leibowitz J, et al. CD4(+) and CD8(+) T cells make discrete contributions to demyelination and neurologic disease in a viral model of multiple sclerosis. J Virol 1998;72:7320-9
   PubMedGoogle Scholar
• Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell 2008;133:775-87
   PubMed Web of Science ®Google Scholar
• Kumar V. Homeostatic control of immunity by TCR peptide-specific tregs. J Clin Invest 2004;114:1222-6
   PubMed Web of Science ®Google Scholar
• Madakamutil LT, Maricic I, Sercarz E, et al. Regulatory T cells control autoimmunity in vivo by inducing apoptotic depletion of activated pathogenic lymphocytes. J Immunol 2003;170:2985-92
   PubMed Web of Science ®Google Scholar
• Hu D, Ikizawa K, Lu L, et al. Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat Immunol 2004;5:516-23
   PubMed Web of Science ®Google Scholar
• Najafian N, Chitnis T, Salama AD, et al. Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. J Clin Invest 2003;112:1037-48
   PubMed Web of Science ®Google Scholar
• Menager-Marcq I, Pomie C, Romagnoli P, et al. CD8+CD28- regulatory T lymphocytes prevent experimental inflammatory bowel disease in mice. Gastroenterology 2006;131:1775-85
   PubMed Web of Science ®Google Scholar
• Gilliet M, Liu YJ. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 2002;195:695-704
   PubMed Web of Science ®Google Scholar
• Faunce DE, Terajewicz A, Stein-Streilein J. Cutting edge: in vitro-generated tolerogenic APC induce CD8+ T regulatory cells that can suppress ongoing experimental autoimmune encephalomyelitis. J Immunol 2004;172:1991-5
   PubMed Web of Science ®Google Scholar
• Chen ML, Yan BS, Kozoriz D, et al. Novel CD8+ treg suppress EAE by TGF-beta- and IFN-gamma-dependent mechanisms. Eur J Immunol 2009;39:3423-35
   PubMedGoogle Scholar
• Lee YH, Ishida Y, Rifa'i M, et al. Essential role of CD8+CD122+ regulatory T cells in the recovery from experimental autoimmune encephalomyelitis. J Immunol 2008;180:825-32
   PubMed Web of Science ®Google Scholar
• Mangalam AK, Luckey D, Giri S, et al. Two discreet subsets of CD8 T cells modulate PLP(91-110) induced experimental autoimmune encephalomyelitis in HLA-DR3 transgenic mice. J Autoimmun 2012;38:344-53
   PubMed Web of Science ®Google Scholar
• Dhib-Jalbut S. Glatiramer acetate (Copaxone) therapy for multiple sclerosis. Pharmacol Ther 2003;98:245-55
   PubMed Web of Science ®Google Scholar
• Karandikar NJ, Crawford MP, Yan X, et al. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest 2002;109:641-9
   PubMed Web of Science ®Google Scholar
• Tennakoon DK, Mehta RS, Ortega SB, et al. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol 2006;176:7119-29
   PubMed Web of Science ®Google Scholar
• Biegler BW, Yan SX, Ortega SB, et al. Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis. J Neuroimmunol 2006;180:159-71
   PubMedGoogle Scholar
• Feger U, Tolosa E, Huang YH, et al. HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. Blood 2007;110:568-77
   PubMed Web of Science ®Google Scholar
• Airas L, Nikula T, Huang YH, et al. Postpartum-activation of multiple sclerosis is associated with down-regulation of tolerogenic HLA-G. J Neuroimmunol 2007;187:205-11
   PubMed Web of Science ®Google Scholar
• Correale J, Villa A. Isolation and characterization of CD8+ regulatory T cells in multiple sclerosis. J Neuroimmunol 2008;195:121-34
   PubMed Web of Science ®Google Scholar
• Correale J, Villa A. Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis. Ann Neurol 2010;67:625-38
   PubMed Web of Science ®Google Scholar
• Hu D, Weiner HL, Ritz J. Identification of cytolytic CD161(-)CD56(+) regulatory CD8 T cells in human peripheral blood. PLoS One 2013;8:e59545
   PubMed Web of Science ®Google Scholar
• Huber M, Heink S, Grothe H, et al. A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity. Eur J Immunol 2009;39:1716-25
   PubMed Web of Science ®Google Scholar
• Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233-40
   PubMed Web of Science ®Google Scholar
• Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006;177:566-73
   PubMed Web of Science ®Google Scholar
• Matusevicius D, Kivisakk P, He B, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999;5:101-4
   PubMed Web of Science ®Google Scholar
• Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008;172:146-55
   PubMed Web of Science ®Google Scholar
• Vanden Eijnden S, Goriely S, De Wit D, et al. IL-23 up-regulates IL-10 and induces IL-17 synthesis by polyclonally activated naive T cells in human. Eur J Immunol 2005;35:469-75
   PubMed Web of Science ®Google Scholar
• Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007;8:639-46
   PubMed Web of Science ®Google Scholar
• Li Y, Chu N, Hu A, et al. Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain 2007;130:490-501
   PubMed Web of Science ®Google Scholar
• Beriou G, Costantino CM, Ashley CW, et al. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 2009;113:4240-9
   PubMed Web of Science ®Google Scholar
• Annibali V, Ristori G, Angelini DF, et al. CD161(high)CD8+T cells bear pathogenetic potential in multiple sclerosis. Brain 2011;134:542-54
   PubMed Web of Science ®Google Scholar
• Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009;10:514-23
   PubMed Web of Science ®Google Scholar
• Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-40
   PubMed Web of Science ®Google Scholar
• Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• Friese MA, Fugger L. Pathogenic CD8(+) T cells in multiple sclerosis. Ann Neurol 2009;66:132-41
   PubMed Web of Science ®Google Scholar
• Crawford MP, Yan SX, Ortega SB, et al. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 2004;103:4222-31
   PubMed Web of Science ®Google Scholar
• Zang YC, Li S, Rivera VM, et al. Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J Immunol 2004;172:5120-7
   PubMed Web of Science ®Google Scholar
• Hemmer B, Vergelli M, Pinilla C, et al. Probing degeneracy in T-cell recognition using peptide combinatorial libraries. Immunol Today 1998;19:163-8
   PubMedGoogle Scholar
• Linda H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009;361:1081-7
   PubMed Web of Science ®Google Scholar